Found: 105
Select item for more details and to access through your institution.
Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials.
- Published in:
- International Journal of Clinical Practice, 2021, v. 75, n. 12, p. 1, doi. 10.1111/ijcp.14975
- By:
- Publication type:
- Article
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
- Published in:
- Rheumatology, 2007, v. 46, n. 7, p. 1122, doi. 10.1093/rheumatology/kem033
- By:
- Publication type:
- Article
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
- Published in:
- Rheumatology, 2007, v. 46, n. 7, p. 1122, doi. 10.1093/rheumatology/kem033
- By:
- Publication type:
- Article
Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis.
- Published in:
- Patient Preference & Adherence, 2023, v. 17, p. 2451, doi. 10.2147/PPA.S427809
- By:
- Publication type:
- Article
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making.
- Published in:
- Patient Preference & Adherence, 2020, v. 14, p. 119, doi. 10.2147/PPA.S220714
- By:
- Publication type:
- Article
Simulating clinical trial visits yields patient insights into study design and recruitment.
- Published in:
- Patient Preference & Adherence, 2017, v. 11, p. 1295, doi. 10.2147/PPA.S137416
- By:
- Publication type:
- Article
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
- Published in:
- Journal of Bone & Mineral Research, 2024, v. 39, n. 3, p. 202, doi. 10.1093/jbmr/zjae016
- By:
- Publication type:
- Article
Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2012, v. 50, n. 3, p. 218, doi. 10.5414/CP201613
- By:
- Publication type:
- Article
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 4, p. 668, doi. 10.1093/mr/roac084
- By:
- Publication type:
- Article
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 1, p. 64, doi. 10.1093/mr/roac020
- By:
- Publication type:
- Article
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
- Published in:
- Modern Rheumatology, 2022, v. 32, n. 2, p. 263, doi. 10.1093/mr/roab030
- By:
- Publication type:
- Article
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
- Published in:
- Rheumatology, 2024, v. 63, n. 4, p. 1058, doi. 10.1093/rheumatology/kead333
- By:
- Publication type:
- Article
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
- Published in:
- Rheumatology, 2023, v. 62, n. 10, p. 3268, doi. 10.1093/rheumatology/kead062
- By:
- Publication type:
- Article
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
- Published in:
- Rheumatology, 2023, v. 62, n. 6, p. 2122, doi. 10.1093/rheumatology/keac605
- By:
- Publication type:
- Article
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
- Published in:
- Rheumatology, 2022, v. 61, n. 12, p. 4797, doi. 10.1093/rheumatology/keac167
- By:
- Publication type:
- Article
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
- Published in:
- Rheumatology, 2022, v. 61, n. 3, p. 1035, doi. 10.1093/rheumatology/keab449
- By:
- Publication type:
- Article
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
- Published in:
- Rheumatology, 2021, v. 60, n. 1, p. 256, doi. 10.1093/rheumatology/keaa234
- By:
- Publication type:
- Article
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis.
- Published in:
- Rheumatology, 2020, v. 59, n. 7, p. 1505, doi. 10.1093/rheumatology/kez471
- By:
- Publication type:
- Article
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
- Published in:
- Rheumatology, 2020, v. 59, n. 2, p. 292, doi. 10.1093/rheumatology/kez265
- By:
- Publication type:
- Article
261 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study.
- Published in:
- Rheumatology, 2018, v. 57, n. 12, p. 2235, doi. 10.1093/rheumatology/key265
- By:
- Publication type:
- Article
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebocontrolled PALACE 4 trial.
- Published in:
- Rheumatology, 2018, v. 57, n. 7, p. 1253, doi. 10.1093/rheumatology/key032
- By:
- Publication type:
- Article
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
- Published in:
- Rheumatology, 2017, v. 56, n. 9, p. 1498, doi. 10.1093/rheumatology/kex174
- By:
- Publication type:
- Article
Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.
- Published in:
- ACR Open Rheumatology, 2023, v. 5, n. 2, p. 63, doi. 10.1002/acr2.11517
- By:
- Publication type:
- Article
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study
- Published in:
- ACR Open Rheumatology, 2022, v. 4, n. 10, p. 903, doi. 10.1002/acr2.11487
- By:
- Publication type:
- Article
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 2, p. 119, doi. 10.1002/acr2.11102
- By:
- Publication type:
- Article
Assessing usability, label comprehension, pen robustness and pharmacokinetics of a selfadministered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis.
- Published in:
- SAGE Open Medicine, 2014, v. 2, p. 1, doi. 10.1177/2050312114564241
- By:
- Publication type:
- Article
A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2023, v. 75, n. 12, p. 2107, doi. 10.1002/art.42637
- By:
- Publication type:
- Article
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study.
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 12, p. 1943, doi. 10.1002/art.42282
- By:
- Publication type:
- Article
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 8, p. 1523, doi. 10.1002/art.41731
- By:
- Publication type:
- Article
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 1, p. 110, doi. 10.1002/art.41477
- By:
- Publication type:
- Article
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
- Published in:
- Arthritis & Rheumatology, 2020, v. 72, n. 10, p. 1621, doi. 10.1002/art.41316
- By:
- Publication type:
- Article
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 11, p. 1824, doi. 10.1002/art.41012
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 12, p. 2283, doi. 10.1002/art.40319
- By:
- Publication type:
- Article
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 5, p. 932, doi. 10.1002/art.40054
- By:
- Publication type:
- Article
A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 12, p. 3104, doi. 10.1002/art.39322
- By:
- Publication type:
- Article
Blockade of Interferon-γ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 10, p. 2713, doi. 10.1002/art.39248
- By:
- Publication type:
- Article
Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 10, p. 2759, doi. 10.1002/art.39234
- By:
- Publication type:
- Article
Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 7, p. 1703, doi. 10.1002/art.39120
- By:
- Publication type:
- Article
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 6, p. 1424, doi. 10.1002/art.39093
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 2, p. 334, doi. 10.1002/art.38949
- By:
- Publication type:
- Article
A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, p. S218, doi. 10.1002/art.38595
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 5, p. 408, doi. 10.1002/cpdd.251
- By:
- Publication type:
- Article
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 259, doi. 10.1002/cpdd.237
- By:
- Publication type:
- Article
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 197, doi. 10.1007/s40259-019-00403-z
- By:
- Publication type:
- Article
Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis: A Randomized Trial.
- Published in:
- Annals of Internal Medicine, 2009, v. 151, n. 4, p. 229, doi. 10.7326/0003-4819-151-4-200908180-00005
- By:
- Publication type:
- Article
Corrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers.
- Published in:
- 2012
- By:
- Publication type:
- Erratum
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2012, v. 107, n. 3, p. 379, doi. 10.1038/ajg.2011.443
- By:
- Publication type:
- Article